nodes	percent_of_prediction	percent_of_DWPC	metapath
Linagliptin—ABCB1—colon cancer	0.741	1	CbGaD
Linagliptin—ABCB1—Irinotecan—colon cancer	0.0437	0.284	CbGbCtD
Linagliptin—ABCB1—Vincristine—colon cancer	0.0382	0.248	CbGbCtD
Linagliptin—CYP3A4—Irinotecan—colon cancer	0.0262	0.17	CbGbCtD
Linagliptin—ABCB1—Methotrexate—colon cancer	0.0231	0.15	CbGbCtD
Linagliptin—CYP3A4—Vincristine—colon cancer	0.0229	0.149	CbGbCtD
Linagliptin—DPP4—blood vessel—colon cancer	0.00664	0.159	CbGeAlD
Linagliptin—DPP4—Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)—CDX2—colon cancer	0.00492	0.292	CbGpPWpGaD
Linagliptin—DPP4—Incretin synthesis, secretion, and inactivation—CDX2—colon cancer	0.00437	0.259	CbGpPWpGaD
Linagliptin—DPP4—embryo—colon cancer	0.00396	0.0949	CbGeAlD
Linagliptin—DPP4—epithelium—colon cancer	0.00323	0.0774	CbGeAlD
Linagliptin—DPP4—smooth muscle tissue—colon cancer	0.00311	0.0746	CbGeAlD
Linagliptin—DPP4—renal system—colon cancer	0.003	0.0718	CbGeAlD
Linagliptin—DPP4—lymphoid tissue—colon cancer	0.00249	0.0596	CbGeAlD
Linagliptin—Bronchial hyperreactivity—Methotrexate—colon cancer	0.00248	0.0541	CcSEcCtD
Linagliptin—DPP4—digestive system—colon cancer	0.00246	0.0589	CbGeAlD
Linagliptin—DPP4—bone marrow—colon cancer	0.00227	0.0543	CbGeAlD
Linagliptin—DPP4—vagina—colon cancer	0.00217	0.052	CbGeAlD
Linagliptin—Diabetic—Methotrexate—colon cancer	0.00194	0.0423	CcSEcCtD
Linagliptin—DPP4—liver—colon cancer	0.00183	0.0439	CbGeAlD
Linagliptin—ABCB1—blood vessel—colon cancer	0.00153	0.0367	CbGeAlD
Linagliptin—Hypertriglyceridaemia—Capecitabine—colon cancer	0.00152	0.0331	CcSEcCtD
Linagliptin—DPP4—Peptide hormone metabolism—CDX2—colon cancer	0.00148	0.088	CbGpPWpGaD
Linagliptin—DPP4—lymph node—colon cancer	0.0014	0.0337	CbGeAlD
Linagliptin—Blood triglycerides increased—Capecitabine—colon cancer	0.00133	0.029	CcSEcCtD
Linagliptin—CYP3A4—renal system—colon cancer	0.000977	0.0234	CbGeAlD
Linagliptin—Pain in extremity—Vincristine—colon cancer	0.00097	0.0211	CcSEcCtD
Linagliptin—DPP4—Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)—CTNNB1—colon cancer	0.000968	0.0574	CbGpPWpGaD
Linagliptin—ABCB1—embryo—colon cancer	0.000914	0.0219	CbGeAlD
Linagliptin—DPP4—Incretin synthesis, secretion, and inactivation—CTNNB1—colon cancer	0.000861	0.0511	CbGpPWpGaD
Linagliptin—Skin exfoliation—Capecitabine—colon cancer	0.000831	0.0181	CcSEcCtD
Linagliptin—Nasopharyngitis—Fluorouracil—colon cancer	0.000809	0.0176	CcSEcCtD
Linagliptin—CYP3A4—digestive system—colon cancer	0.000802	0.0192	CbGeAlD
Linagliptin—Pancreatitis—Irinotecan—colon cancer	0.0008	0.0174	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Irinotecan—colon cancer	0.000758	0.0165	CcSEcCtD
Linagliptin—ABCB1—epithelium—colon cancer	0.000746	0.0179	CbGeAlD
Linagliptin—Diabetes mellitus—Capecitabine—colon cancer	0.000727	0.0158	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Fluorouracil—colon cancer	0.000726	0.0158	CcSEcCtD
Linagliptin—Infestation—Fluorouracil—colon cancer	0.000697	0.0152	CcSEcCtD
Linagliptin—Infestation NOS—Fluorouracil—colon cancer	0.000697	0.0152	CcSEcCtD
Linagliptin—ABCB1—renal system—colon cancer	0.000692	0.0166	CbGeAlD
Linagliptin—Urinary tract infection—Fluorouracil—colon cancer	0.000677	0.0148	CcSEcCtD
Linagliptin—Pain in extremity—Capecitabine—colon cancer	0.000632	0.0138	CcSEcCtD
Linagliptin—Skin exfoliation—Methotrexate—colon cancer	0.000619	0.0135	CcSEcCtD
Linagliptin—Mediastinal disorder—Vincristine—colon cancer	0.000604	0.0132	CcSEcCtD
Linagliptin—CYP3A4—liver—colon cancer	0.000597	0.0143	CbGeAlD
Linagliptin—Immune system disorder—Irinotecan—colon cancer	0.00059	0.0129	CcSEcCtD
Linagliptin—Mediastinal disorder—Irinotecan—colon cancer	0.000589	0.0128	CcSEcCtD
Linagliptin—ABCB1—lymphoid tissue—colon cancer	0.000574	0.0138	CbGeAlD
Linagliptin—ABCB1—digestive system—colon cancer	0.000567	0.0136	CbGeAlD
Linagliptin—Nasopharyngitis—Capecitabine—colon cancer	0.000565	0.0123	CcSEcCtD
Linagliptin—Back pain—Vincristine—colon cancer	0.000565	0.0123	CcSEcCtD
Linagliptin—Back pain—Irinotecan—colon cancer	0.00055	0.012	CcSEcCtD
Linagliptin—Diabetes mellitus—Methotrexate—colon cancer	0.000541	0.0118	CcSEcCtD
Linagliptin—ABCB1—bone marrow—colon cancer	0.000523	0.0125	CbGeAlD
Linagliptin—Upper respiratory tract infection—Capecitabine—colon cancer	0.000508	0.0111	CcSEcCtD
Linagliptin—ABCB1—vagina—colon cancer	0.000501	0.012	CbGeAlD
Linagliptin—Myalgia—Vincristine—colon cancer	0.000497	0.0108	CcSEcCtD
Linagliptin—Weight increased—Capecitabine—colon cancer	0.000497	0.0108	CcSEcCtD
Linagliptin—Cough—Irinotecan—colon cancer	0.000496	0.0108	CcSEcCtD
Linagliptin—Infestation—Capecitabine—colon cancer	0.000487	0.0106	CcSEcCtD
Linagliptin—Infestation NOS—Capecitabine—colon cancer	0.000487	0.0106	CcSEcCtD
Linagliptin—Anaphylactic shock—Vincristine—colon cancer	0.000477	0.0104	CcSEcCtD
Linagliptin—Infection—Vincristine—colon cancer	0.000473	0.0103	CcSEcCtD
Linagliptin—Urinary tract infection—Capecitabine—colon cancer	0.000473	0.0103	CcSEcCtD
Linagliptin—Anaphylactic shock—Irinotecan—colon cancer	0.000464	0.0101	CcSEcCtD
Linagliptin—Myalgia—Fluorouracil—colon cancer	0.000464	0.0101	CcSEcCtD
Linagliptin—Infection—Irinotecan—colon cancer	0.000461	0.0101	CcSEcCtD
Linagliptin—Anaphylactic shock—Fluorouracil—colon cancer	0.000444	0.00969	CcSEcCtD
Linagliptin—Infection—Fluorouracil—colon cancer	0.000442	0.00963	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Vincristine—colon cancer	0.000434	0.00947	CcSEcCtD
Linagliptin—ABCB1—liver—colon cancer	0.000423	0.0101	CbGeAlD
Linagliptin—Gastrointestinal disorder—Vincristine—colon cancer	0.000411	0.00897	CcSEcCtD
Linagliptin—Constipation—Vincristine—colon cancer	0.000407	0.00889	CcSEcCtD
Linagliptin—CYP3A4—Codeine and Morphine Metabolism—ABCB1—colon cancer	0.000405	0.024	CbGpPWpGaD
Linagliptin—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000405	0.00883	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Irinotecan—colon cancer	0.000401	0.00874	CcSEcCtD
Linagliptin—Pancreatitis—Methotrexate—colon cancer	0.000399	0.00869	CcSEcCtD
Linagliptin—Constipation—Irinotecan—colon cancer	0.000397	0.00865	CcSEcCtD
Linagliptin—Immune system disorder—Capecitabine—colon cancer	0.000395	0.00861	CcSEcCtD
Linagliptin—Mediastinal disorder—Capecitabine—colon cancer	0.000394	0.00859	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000384	0.00837	CcSEcCtD
Linagliptin—Malnutrition—Capecitabine—colon cancer	0.000381	0.0083	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Methotrexate—colon cancer	0.000378	0.00824	CcSEcCtD
Linagliptin—Back pain—Capecitabine—colon cancer	0.000368	0.00803	CcSEcCtD
Linagliptin—Infestation—Methotrexate—colon cancer	0.000363	0.00791	CcSEcCtD
Linagliptin—Infestation NOS—Methotrexate—colon cancer	0.000363	0.00791	CcSEcCtD
Linagliptin—Urticaria—Fluorouracil—colon cancer	0.000353	0.0077	CcSEcCtD
Linagliptin—Hypersensitivity—Vincristine—colon cancer	0.000351	0.00766	CcSEcCtD
Linagliptin—Hypersensitivity—Irinotecan—colon cancer	0.000342	0.00746	CcSEcCtD
Linagliptin—Cough—Capecitabine—colon cancer	0.000332	0.00724	CcSEcCtD
Linagliptin—Hypersensitivity—Fluorouracil—colon cancer	0.000327	0.00714	CcSEcCtD
Linagliptin—Diarrhoea—Vincristine—colon cancer	0.000326	0.00711	CcSEcCtD
Linagliptin—ABCB1—lymph node—colon cancer	0.000324	0.00777	CbGeAlD
Linagliptin—Myalgia—Capecitabine—colon cancer	0.000324	0.00706	CcSEcCtD
Linagliptin—Arthralgia—Capecitabine—colon cancer	0.000324	0.00706	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000322	0.00702	CcSEcCtD
Linagliptin—Diarrhoea—Irinotecan—colon cancer	0.000318	0.00692	CcSEcCtD
Linagliptin—Infection—Capecitabine—colon cancer	0.000309	0.00673	CcSEcCtD
Linagliptin—Diarrhoea—Fluorouracil—colon cancer	0.000304	0.00663	CcSEcCtD
Linagliptin—Skin disorder—Capecitabine—colon cancer	0.000302	0.00658	CcSEcCtD
Linagliptin—Rash—Vincristine—colon cancer	0.0003	0.00655	CcSEcCtD
Linagliptin—Dermatitis—Vincristine—colon cancer	0.0003	0.00655	CcSEcCtD
Linagliptin—Headache—Vincristine—colon cancer	0.000299	0.00651	CcSEcCtD
Linagliptin—Immune system disorder—Methotrexate—colon cancer	0.000294	0.00641	CcSEcCtD
Linagliptin—Mediastinal disorder—Methotrexate—colon cancer	0.000293	0.0064	CcSEcCtD
Linagliptin—Rash—Irinotecan—colon cancer	0.000293	0.00638	CcSEcCtD
Linagliptin—Dermatitis—Irinotecan—colon cancer	0.000292	0.00637	CcSEcCtD
Linagliptin—DPP4—Peptide hormone metabolism—CTNNB1—colon cancer	0.000292	0.0173	CbGpPWpGaD
Linagliptin—Headache—Irinotecan—colon cancer	0.000291	0.00634	CcSEcCtD
Linagliptin—Malnutrition—Methotrexate—colon cancer	0.000283	0.00618	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000283	0.00617	CcSEcCtD
Linagliptin—CYP3A4—Metapathway biotransformation—CHST4—colon cancer	0.000283	0.0168	CbGpPWpGaD
Linagliptin—Rash—Fluorouracil—colon cancer	0.00028	0.00611	CcSEcCtD
Linagliptin—Dermatitis—Fluorouracil—colon cancer	0.00028	0.00611	CcSEcCtD
Linagliptin—DPP4—Metabolism of proteins—CDX2—colon cancer	0.00028	0.0166	CbGpPWpGaD
Linagliptin—Headache—Fluorouracil—colon cancer	0.000278	0.00607	CcSEcCtD
Linagliptin—Back pain—Methotrexate—colon cancer	0.000274	0.00598	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Capecitabine—colon cancer	0.000268	0.00585	CcSEcCtD
Linagliptin—Constipation—Capecitabine—colon cancer	0.000266	0.00579	CcSEcCtD
Linagliptin—Cough—Methotrexate—colon cancer	0.000247	0.00539	CcSEcCtD
Linagliptin—Urticaria—Capecitabine—colon cancer	0.000247	0.00538	CcSEcCtD
Linagliptin—Myalgia—Methotrexate—colon cancer	0.000241	0.00526	CcSEcCtD
Linagliptin—Arthralgia—Methotrexate—colon cancer	0.000241	0.00526	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.00024	0.00522	CcSEcCtD
Linagliptin—DPP4—Metabolism of proteins—MUC2—colon cancer	0.000238	0.0141	CbGpPWpGaD
Linagliptin—Anaphylactic shock—Methotrexate—colon cancer	0.000231	0.00504	CcSEcCtD
Linagliptin—Infection—Methotrexate—colon cancer	0.00023	0.00501	CcSEcCtD
Linagliptin—Hypersensitivity—Capecitabine—colon cancer	0.000229	0.00499	CcSEcCtD
Linagliptin—Skin disorder—Methotrexate—colon cancer	0.000225	0.0049	CcSEcCtD
Linagliptin—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—colon cancer	0.000222	0.0132	CbGpPWpGaD
Linagliptin—Diarrhoea—Capecitabine—colon cancer	0.000213	0.00463	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000211	0.00459	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Methotrexate—colon cancer	0.0002	0.00435	CcSEcCtD
Linagliptin—Rash—Capecitabine—colon cancer	0.000196	0.00427	CcSEcCtD
Linagliptin—Dermatitis—Capecitabine—colon cancer	0.000196	0.00427	CcSEcCtD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—HNF4A—colon cancer	0.000195	0.0116	CbGpPWpGaD
Linagliptin—Headache—Capecitabine—colon cancer	0.000195	0.00424	CcSEcCtD
Linagliptin—CYP3A4—Irinotecan Pathway—APC—colon cancer	0.000187	0.0111	CbGpPWpGaD
Linagliptin—Urticaria—Methotrexate—colon cancer	0.000184	0.00401	CcSEcCtD
Linagliptin—Hypersensitivity—Methotrexate—colon cancer	0.00017	0.00371	CcSEcCtD
Linagliptin—Diarrhoea—Methotrexate—colon cancer	0.000158	0.00345	CcSEcCtD
Linagliptin—Rash—Methotrexate—colon cancer	0.000146	0.00318	CcSEcCtD
Linagliptin—Dermatitis—Methotrexate—colon cancer	0.000146	0.00318	CcSEcCtD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—colon cancer	0.000145	0.0086	CbGpPWpGaD
Linagliptin—Headache—Methotrexate—colon cancer	0.000145	0.00316	CcSEcCtD
Linagliptin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000144	0.00853	CbGpPWpGaD
Linagliptin—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000134	0.00793	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—CHST5—colon cancer	0.00013	0.00771	CbGpPWpGaD
Linagliptin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000127	0.00755	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	9.89e-05	0.00587	CbGpPWpGaD
Linagliptin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	8.86e-05	0.00526	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	8.32e-05	0.00494	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	6.66e-05	0.00395	CbGpPWpGaD
Linagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—colon cancer	6.12e-05	0.00363	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CA7—colon cancer	6.03e-05	0.00358	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—EP300—colon cancer	5.53e-05	0.00328	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—CTNNB1—colon cancer	5.51e-05	0.00327	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—CASP3—colon cancer	5.35e-05	0.00317	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—colon cancer	5.24e-05	0.00311	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	5.1e-05	0.00303	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	4.92e-05	0.00292	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—VEGFA—colon cancer	4.54e-05	0.00269	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—TGFB1—colon cancer	4.17e-05	0.00247	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—APC—colon cancer	3.75e-05	0.00222	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CA7—colon cancer	3.72e-05	0.00221	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ODC1—colon cancer	3.66e-05	0.00217	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CHST5—colon cancer	3.66e-05	0.00217	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—AKT1—colon cancer	3.34e-05	0.00198	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	2.84e-05	0.00169	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	2.64e-05	0.00157	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	2.57e-05	0.00152	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	2.54e-05	0.00151	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	2.49e-05	0.00147	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	2.36e-05	0.0014	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	2.3e-05	0.00136	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ODC1—colon cancer	2.25e-05	0.00134	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CHST5—colon cancer	2.25e-05	0.00134	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	2.24e-05	0.00133	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	2.06e-05	0.00122	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	2.06e-05	0.00122	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	2.02e-05	0.0012	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	1.9e-05	0.00113	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	1.75e-05	0.00104	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	1.69e-05	0.001	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	1.43e-05	0.000848	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—TYMS—colon cancer	9.49e-06	0.000563	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PPARG—colon cancer	6.72e-06	0.000399	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ABCB1—colon cancer	5.95e-06	0.000353	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—TYMS—colon cancer	5.85e-06	0.000347	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PTGS2—colon cancer	5.29e-06	0.000314	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—EP300—colon cancer	4.4e-06	0.000261	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PPARG—colon cancer	4.14e-06	0.000246	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PTGS2—colon cancer	3.26e-06	0.000193	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PIK3CA—colon cancer	3.25e-06	0.000193	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—EP300—colon cancer	2.71e-06	0.000161	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—AKT1—colon cancer	2.66e-06	0.000158	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PIK3CA—colon cancer	2e-06	0.000119	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—AKT1—colon cancer	1.64e-06	9.71e-05	CbGpPWpGaD
